Welcome to our dedicated page for Karyopharm Therapeutics news (Ticker: $KPTI), a resource for investors and traders seeking the latest updates and insights on Karyopharm Therapeutics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Karyopharm Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Karyopharm Therapeutics's position in the market.
Karyopharm Therapeutics presented updated subgroup analyses from the SIENDO study at the 2024 ASCO Meeting, focusing on advanced or recurrent TP53 wild-type endometrial cancer. Key findings include a median progression-free survival (PFS) of 28.4 months for selinexor-treated patients versus 5.2 months for the placebo group. Additionally, a quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis showed a mean of 26 months for selinexor compared to 15 months for placebo. No new safety signals were identified. The exploratory subgroup analysis highlighted promising efficacy signals, with ongoing Phase 3 trials expected to provide definitive results by mid-2025.
Karyopharm Therapeutics (Nasdaq: KPTI) announced that its senior management will participate in the Jefferies Global Healthcare Conference on June 5, 2024, in New York. The event includes a fireside chat at 1:00 p.m. ET. A live webcast and slides will be available on the company's website under the 'Events & Presentations' section and for replay afterward.
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) will participate in the 2024 RBC Capital Markets Global Healthcare Conference with a fireside chat on May 15. The live webcast can be accessed on the company's website.
Karyopharm Therapeutics Inc. announced significant refinancing transactions, extending the vast majority of its debt maturities to 2028 and 2029. The company exchanged $148.0 million of existing convertible notes due in 2025 for $111.0 million of new convertible notes due in 2029 and warrants. Additionally, a new $100.0 million senior secured term loan was issued, repaying principal portions and amending a royalty agreement with HealthCare Royalty. These transactions fortify the company's balance sheet and enhance its ability to unlock the potential of selinexor.
Karyopharm Therapeutics Inc. reported first-quarter 2024 financial results, highlighting revenue of $33.1 million, with $26.0 million from U.S. XPOVIO net product revenue. The company reaffirmed its full-year revenue guidance of $140.0 million to $160.0 million, including U.S. XPOVIO net product revenue guidance of $100.0 million to $120.0 million. Karyopharm made significant refinancing transactions and amended a royalty agreement to extend debt maturities into 2028 and 2029, strengthening its position for future growth. The company also presented data from the Phase 3 SIENDO trial of Selinexor maintenance treatment in endometrial cancer patients at the 2024 ASCO Annual Meeting.
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) will report its first quarter 2024 financial results on May 8, 2024. The management team will host a conference call and audio webcast to discuss the financial results and other updates. Investors can access the call and webcast through the company's website.
Karyopharm Therapeutics Inc. granted 72,700 restricted stock units (RSUs) to five new employees on April 30, 2024, under the 2022 Inducement Stock Incentive Plan. These RSUs will vest over three years, with 33 1/3% vesting annually. The awards are subject to continued service and can be fully exercisable in case of a 'change in control event' within the first year.
